ArticleInternational journal of retina and vitreous2026
Correlations between SS-OCT and OCT angiography biomarkers in treatment-naïve neovascular AMD during aflibercept therapy: a prospective study.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSwept-source OCT (SS-OCT) and OCT angiography (SS-OCTA) enable high-resolution assessment of retinal and choroidal biomarkers in neovascular AMD (nAMD). However, prospective analyses and how these biomarkers correlate before and after therapy are limited. The aim of this study was to prospectively evaluate biomarker correlations following a loading dose of aflibercept using state-of-the-art, high-resolution imaging with SS-OCT and SS-OCTA over the course of a 4-month follow-up in treatment-naïve nAMD.
methodsThis prospective interventional case series study included 21 eyes from 21 treatment-naïve patients with nAMD. All eyes received three monthly intravitreal aflibercept injections. Patients were evaluated at baseline and one month after the loading phase (4-month visit). The biomarkers included the best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), macular neovascularization area (MNVA), vessel density (VD), and avascular area of the superficial plexus (AASP) and deep plexus (AADP). Pre (baseline) and posttreatment values were compared, and correlations were analyzed using Pearson’s or Spearman’s methods.
resultsSignificant functional, structural, and vascular improvements in all the evaluated biomarkers except intraocular pressure were observed after treatment. The mean BCVA improved from 1.11 ± 0.47 to 0.56 ± 0.20 logMAR (p < 0.001). SS-OCT (CMT and CCT), and SS-OCTA (MNVA, AASP and AADP) metrics were significantly lower following treatment. Correlation analysis revealed multiple statistically significant associations among structural, functional, and vascular biomarkers. The baseline CMT showed a moderate positive correlation with the CMT posttreatment (r = 0.53; p = 0.013) and a very high negative correlation with CMT reduction (r = − 0.95; p < 0.001). The baseline CCT was highly correlated with CCT posttreatment (r = 0.87; p = 0.002). The BCVA correlated significantly with CMT at baseline and posttreatment. Notably, the baseline MNVA was moderately negatively correlated with the posttreatment CCT (r = − 0.51; p = 0.019). Significant correlations were also identified between the AADP and both the baseline CMT and CMT reduction, as well as between changes in AASP and CCT. These findings highlight complex and interdependent relationships among retinal thickness, choroidal structure, visual function, and OCTA-derived microvascular biomarkers following aflibercept therapy.
conclusionsIn treatment-naïve eyes with nAMD, aflibercept loading therapy induces significant and coordinated functional, structural, and microvascular changes. The observed correlations demonstrate that baseline SS-OCT and SS-OCTA biomarkers not only reflect initial disease burden but are also closely associated with the magnitude and direction of anatomical and vascular remodeling after treatment. These findings support the value of integrated multimodal biomarker assessment for improving prognostic stratification and advancing individualized management strategies in treatment-naïve nAMD. These findings are novel and have not been previously reported in the literature. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.